Accredo (Evernorth Health Services)

Overview

Accredo is the specialty pharmacy division of Evernorth Health Services, itself a subsidiary of The Cigna Group (NYSE: CI). By dispensing revenue, Accredo is the #2 specialty pharmacy in the United States at $59.5B (2023), behind only CVS Specialty. Accredo’s scale is driven by its integration with Express Scripts, the largest PBM in the U.S. with approximately 120 million covered lives — providing a captive patient pipeline that independent specialty pharmacies cannot replicate. (Source: raw/research/accredo-evernorth.pplx.md)

Accredo’s clinical model is organized around 15 condition-specific Therapeutic Resource Centers (TRCs), each staffed with pharmacists, nurses, and patient care coordinators who specialize in a single disease state. This therapeutic specialization — combined with PBM integration, massive scale, and the GeneAXS gene therapy team — makes Accredo the benchmark against which all other specialty pharmacies are measured.

The Evernorth platform also includes CuraScript SD (specialty distribution for buy-and-bill), creating a full-spectrum specialty pharmacy + distribution capability within a single corporate entity.

Services & Capabilities

15 Therapeutic Resource Centers (TRCs)

Accredo’s clinical model is organized into dedicated TRCs, each with disease-specific clinical expertise:

1. Oncology TRC: Oral oncolytics, supportive care; data shows +7 months median survival advantage for Accredo-managed oncology patients vs comparator
2. Fertility TRC (Freedom Fertility): One of the largest fertility pharmacy programs nationally
3. Multiple Sclerosis TRC: All MS DMTs; adherence and clinical monitoring
4. Pulmonary TRC: PAH, asthma biologics, COPD
5. Rare Disease TRC: Ultra-rare therapies, complex PA navigation
6. Inflammatory TRC: TNF inhibitors, IL-17/IL-23, JAK inhibitors for RA, IBD, psoriasis
7. Bleeding Disorders TRC: Factor replacement, emicizumab, gene therapy
8. HIV TRC: ART regimens, PrEP
9. Hepatitis C TRC: DAA therapy management
10. Transplant TRC: Immunosuppression management
11. Growth Hormone TRC: Pediatric and adult GH deficiency
12. Immunoglobulin TRC: IVIg and SCIg for PID, CIDP
13. Neurology TRC: Beyond MS — epilepsy, migraine, neuromuscular
14. Dermatology TRC: Biologic therapies for psoriasis, atopic dermatitis
15. Additional TRCs: Expanded to cover 300+ therapeutic areas total

GeneAXS Gene Therapy Team

Accredo’s dedicated cell/gene therapy platform:

• Payer contracting: Navigates complex gene therapy reimbursement ($1-3M per treatment)
• Clearance & authorization: Specialized PA for gene therapies with outcomes-based contracting
• Fulfillment: Temperature-controlled, just-in-time delivery to treatment centers
• 50%+ of exclusive gene therapies are rare disease — positioning GeneAXS at the intersection of CGT and rare disease
• Competes with Orsini (12 CGTs) and PANTHERx Rare (RxARECONCIERGE) for gene therapy designations

Patient Experience & Digital

• 97% first-call resolution rate
• 98% patient satisfaction score
• 70% of patients actively using the digital app
• MyAccredoPatients.com: Prescriber portal; 75% of U.S. specialty prescribers registered
• Digital refill management, delivery tracking, and clinical communication

Specialty Distribution — CuraScript SD

Sister entity within Evernorth providing:

• Buy-and-bill specialty drug distribution to physician offices and health systems
• Complements Accredo’s patient-direct dispensing with provider-direct distribution
• Co-located with Accredo at Newark, DE facility (October 2025)

Express Scripts PBM Integration

The defining structural advantage:

• ~120 million covered lives through Express Scripts
• Formulary management drives prescription volume to Accredo
• Prior authorization and benefits verification embedded in PBM workflow
• Closed-loop data from prescription to outcomes
• ESI formulary exclusion list: 460+ products (drives volume concentration)

Competitive Position

Accredo’s competitive position is defined by its vertical integration within the Cigna/Evernorth stack:

• #2 SP by revenue: $59.5B dispensing revenue (2023). Only CVS Specialty is larger. Scale provides unmatched payer leverage, manufacturer negotiating power, and operational efficiency.
• PBM captive lives: ~120M Express Scripts lives create a captive pipeline that independent SPs (PANTHERx, Orsini, BrightSpring) cannot replicate. This is both the greatest strength and the greatest source of regulatory/political risk.
• TRC clinical model: 15 disease-specific TRCs with dedicated clinical staff is deeper therapeutic specialization than most competitors offer.
• Full-spectrum: Accredo (patient-direct SP) + CuraScript SD (provider-direct distribution) + Express Scripts (PBM) = complete specialty drug value chain.

Key competitors: CVS Specialty (#1 by revenue), Optum Specialty/OptumRx (#3), BrightSpring/Onco360 (largest independent), PANTHERx Rare and Orsini (rare disease niche).

Recent Developments

• September 2025: Evernorth made a $3.5B preferred equity investment in Shields Health Solutions — a non-controlling stake in the leading health system SP accelerator. This gives Evernorth exposure to the health system SP channel without direct ownership.
• October 2025: Newark, Delaware facility opened — approximately 200,000 sq ft co-locating Accredo and CuraScript SD operations. Consolidation of dispensing and distribution for operational efficiency.
• February 2026: FTC consent order with Express Scripts requiring elimination of spread pricing practices and enhanced formulary transparency. A significant regulatory development that may impact Evernorth’s specialty pharmacy economics.
• March 2024: TRICARE specialty pharmacy benefit transition — Accredo began serving military beneficiaries under the TRICARE contract, adding a large government population.
• ESI formulary management: Express Scripts’ formulary exclusion list (460+ products) continues to be a lever driving prescription volume concentration through Accredo.

Client & Partner Ecosystem

PBM/Health Plan Integration

• Express Scripts: ~120M covered lives; formulary management, PA automation, claims processing
• Cigna Healthcare: Direct integration with Cigna’s health plan members
• TRICARE: Military beneficiary specialty pharmacy (since March 2024)

Manufacturer Relationships

• GeneAXS partnerships with gene therapy manufacturers
• Broad formulary spanning 300+ therapeutic areas
• ESI formulary exclusion list (460+ products) gives Accredo leverage in manufacturer negotiations

Health System Relationships

• CuraScript SD serves buy-and-bill physician offices and health systems
• Shields Health Solutions investment provides indirect health system SP channel access

Investor/Owner

• Cigna Group (NYSE: CI): Full ownership through Evernorth Health Services
• Evernorth also holds investments in Shields Health Solutions ($3.5B) and CarePathRx

Technology Platform

IceGen Cold Chain Algorithm

Proprietary cold chain management technology:

• 99% dispensing accuracy for temperature-sensitive specialty drugs
• Predictive algorithms optimizing packaging and shipping routes
• Critical for biologics, gene therapies, and other temperature-sensitive products

Digital Patient Platform

• Mobile app (70% patient adoption)
• Digital refill, delivery tracking, clinical messaging
• Integrated with Express Scripts member portal

MyAccredoPatients.com — Prescriber Portal

• 75% of U.S. specialty prescribers registered
• Electronic prescribing, PA status tracking, patient status updates
• Specialty-specific clinical tools and formulary information

PBM Integration Technology

• Real-time benefits verification via Express Scripts
• Automated prior authorization workflows
• Closed-loop outcomes data from Rx to clinical outcomes
• Formulary optimization and step-therapy management

Therapeutic Focus

Accredo’s 15 TRCs cover the full spectrum of specialty therapeutics:

• Oncology: Oral oncolytics (+7 months survival data); largest single therapy category
• Immunology/Inflammatory: TNF, IL-17/23, JAK inhibitors for RA, IBD, psoriasis, atopic dermatitis
• Neurology: MS (all DMTs), epilepsy, migraine, neuromuscular
• Rare disease: Ultra-rare therapies, gene therapy (GeneAXS)
• Fertility: Freedom Fertility — one of the largest fertility pharmacy programs
• Hematology: Bleeding disorders, hemophilia gene therapies
• HIV/Infectious disease: Full ART formulary, PrEP
• Immunoglobulin: IVIg/SCIg for PID, CIDP
• Pulmonary: PAH, asthma/COPD biologics
• Transplant: Immunosuppression management
• Dermatology: Biologic therapies

Sources

• Accredo / Evernorth research